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In the 70 years following the first description of the benefits of surgical castration, despite advances in medical therapy e.g.
cabazitaxel, enzalutamide, abiraterone, androgen deprivation therapy (ADT) remains the cornerstone of treatment for advanced
prostate cancer. However, with increasing numbers of men undergoing PSA testing, the disease is being diagnosed earlier and the
costs of ADT, with uncertain survival benefits and associated risks, have risen dramatically. Clinical studies of potent novel agents have
shown survival benefits in advanced disease, but timing, risks and cost-effectiveness of treatment remain controversial. As new agents
enter clinical practice, a comprehensive research strategy is essential to optimise benefits whilst minimising harm.
INTRODUCTION
Prostate cancer is the sixth most common cause of cancer
mortality worldwide (268 000 deaths recorded in 2008). There is
considerable discrepancy between reported incidence and mortality
(Figure 1), particularly in the developed world attributable mainly
to prostate specific antigen (PSA) testing. A significant number of
men diagnosed with prostate cancer will survive for many years,
even without radical curative treatment. Endocrine therapy is the
mainstay of treatment for advanced prostate cancer. It has been
reported that nearly 50% of all men diagnosed with prostate cancer
will undergo androgen deprivation therapy (ADT) at some stage
after diagnosis (Meng et al, 2002) and men remain on such
treatment for up to two decades (Schroder et al, 2009). Despite
trends in a reduction of inappropriate ADT use in the USA
(Shahinian et al, 2010) the situation in other health care systems
where these agents are widespread, such as the UK, remains
uncertain. Part of the problem in evaluating the size of the issue is
that in most countries, data on the precise timing of ADT in men
with prostate cancer are not routinely collected. Guidelines
produced by the European Association of Urology (Mottet et al,
2011), the National Comprehensive Cancer Network (NCCN,
2012), and The British Association of Urological Surgeons (BAUS,
2009) refer to caution being exercised with regards to timing of
introduction of ADT in men with advanced prostate cancer,
however controversy surrounds the concept of what constitutes
‘early’ or ‘late’ in this context.
Observational evidence has been accumulating suggesting that
men on long-term conventional ADT may be at risk of treatment-
related adverse events, in particular cardiovascular disease (CVD)
(Bourke et al, 2011). Links have already been made between low
testosterone levels (hypogonadism) and CVD in other settings
(Malkin et al, 2010). The severe iatrogenic hypogonadal state
induced by medical or surgical castration to treat prostate cancer
could augment CVD risk in these men.
What of the costs of such therapy? With increasing lead-time
bias and thus treatment duration, costs are spiralling upwards.
Data from the 2010 NHS prescription cost analysis reports that
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around d100million was spent on ADT in England (inclusive of
Bicalutamide, Buserelin, Cyproterone Acetate, Degarelix, Fluta-
mide, Goserelin Acetate, Leuprorelin Acetate and Triptorelin
Acetate) (The NHS Information Centre PSU, 2010). This
represents 28% of the total spend on malignant disease &
immunosuppressive drugs. The situation in the United States is
similar and this probably reflects the situation in every healthcare
system in the developed world.
In the context of burgeoning costs and accumulating evidence of
risk of ADT, closer scrutiny of the risks and benefits of ADT for
advanced prostate cancer is warranted. This is particularly relevant
given the recent introduction of the novel androgen synthesis
inhibitor, abiraterone (de Bono et al, 2011) and reported similar
improved survival results for enzalutamide, a first-in-class andro-
gen inhibitor (Scher et al, 2012) in men with chemotherapy
relapsed castrate-resistant prostate cancer. Demonstration of
efficacy in such late-stage disease will certainly lead to investigation
of these treatments earlier in the disease.
THE HISTORY OF ENDOCRINE THERAPY IN PROSTATE
CANCER
Charles Huggins (Huggins and Hodges, 1941) demonstrated the
effectiveness of orchiectomy in palliating symptomatic metastatic
prostate cancer. Several large studies carried out in the ‘60s and
‘70s (VACURG series) established the role of endocrine therapy in
mainstream clinical practice by showing equivalent benefit of
orchiectomy and of Diethylstilboestrol (DES) in providing effective
palliation in end-stage disease, but evidence for improvement in
survival remained elusive. With time, it became evident that high-
dose DES was associated with excess cardiovascular mortality (de
Voogt et al, 1986) which manifested as early as the first six months
of treatment. First-line treatment with oestrogens was all but
forgotten for the next 30 years.
The clinical picture in prostate cancer has been dramatically
altered by prostate-specific antigen (PSA) testing and by the use of
luteinizing hormone-releasing hormone (LHrH) analogues (Tolis
et al, 1982; Waxman et al, 1983). On the one hand, men are being
diagnosed earlier with prostate cancer creating significant lead-
time bias. On the other, the availability of medical castration,
apparently without excess morbidity (Waxman et al, 1983) has
meant removal of the negative connotations of surgical castration,
thus improving the acceptability of such treatment to both patients
and clinicians. The result is that despite evidence of superior cost-
effectiveness of surgical castration, LHrH agonists have become the
predominant mode of castration, often instituted earlier in the
disease than originally intended when castration for advanced
prostate cancer was first described.
Is ADT beneficial?. There is good evidence for the use of ADT,
either in the form of orchiectomy or LHrH analogues, in advanced
symptomatic metastatic prostate cancer. The benefits are mostly in
palliation of symptoms. There have been very few studies
comparing the use of endocrine therapy at any stage in prostate
cancer to no hormonal therapy at all. As prostate cancer progresses
and becomes symptomatic most men are placed on ADT. Hence,
the existing research has sought to assess whether ‘early’ versus
‘late’ ADT prolongs life significantly. There is weak evidence of
improved overall survival but only at 10 years with immediate
ADT compared with deferred ADT (absolute risk reduction¼
5.5%) from a Cochrane review of early vs. deferred ADT in the
treatment of advanced prostate cancer (Nair et al, 2002). However,
the number of patients available for analysis at 10 years of follow-
up was small and relied almost exclusively on a single VACURG
study from the pre-PSA era using castration by orchiectomy rather
than LHrH analogues (Jordan et al, 1977). Furthermore, the review
authors reported important caveats that the trials which were
synthesised had different control comparisons, heterogenous
definitions of disease progression and none had validated
assessments of prostate cancer specific mortality. As such,
conclusive evidence of prostate cancer survival when ADT is
initiated at diagnosis compared to waiting until emergence of
symptomatic metastatic disease remains limited (Studer et al, 2006;
Schroder et al, 2009). The updated results of EORTC 30891
comparing immediate ADT to deferred treatment initiated at the
time of symptomatic disease progression or life-threatening
complications showed a modest improvement in overall survival
(HR¼ 1.21) favouring immediate treatment (Studer et al, 2011).
The cumulative mortality due to prostate cancer at 10-years was
almost identical (22.2% and 21.0%) in the deferred and immediate
arms respectively. It is important to point out that the study was
originally designed to demonstrate non-inferiority of deferred
treatment.
In contrast, the use of ADT in the context of multimodal
therapy (i.e. in combination with radical prostatectomy or
radiotherapy) has a more established evidence base (Kumar et al,
2006; Payne and Mason, 2011). ADT use of variable duration
(from 6 months of ADT to orchietomy), in association with radical
local treatment (e.g. for established lymphatic metastases following
radical prostatectomy or in combination with radiotherapy in
locally advanced disease), has been reported to improve overall and
cancer specific survival. The evidence for radiotherapy is consider-
ably stronger than that for surgery (Widmark et al, 2009; Verhagen
et al, 2010). Two trials assessing combined radiotherapy with
androgen deprivation have reported results of 71.5% overall
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survival at 5 years (Mottet et al, 2012) and a 39% cumulative
overall mortality at 10 years (Widmark et al, 2009) in their ADT
monotherapy arms. However, as neither trial was designed to
assess incidence of iatrogenic harm or included a true control
group i.e. a comparison of treatment without ADT, it is not
possible to say whether ADT contributed significantly to the
survival figures reported. There was a definite advantage in the
group treated with combined ADT and radiotherapy over ADT
alone at around 7 years of follow-up. Thus evidence for benefit in
terms of efficacy can be said to exist when ADT is combined with
radical local therapy, but only in men with sufficient life-
expectancy to benefit. It is generally considered that the radio-
sensitising effect of ADT is an important mechanism for improved
outcomes in radiation therapy trials (Payne and Mason, 2011)
rather than any effect on micrometastases.
Can ADT do harm?. Outside the context of ADT in prostate
cancer, there are multiple links between low androgen levels and
CVD; low levels of androgens are commonly observed in patients
with established coronary heart disease and heart failure. Over the
last decade, various mechanisms whereby the effects of ADT could
adversely affect CVD risk profile have been proposed including
increase in body fat, reduction in lean mass, hyperlipidemia and
changes in fasting plasma insulin/ fasting glucose levels (Bourke
et al, 2011). Observational evidence associates the use of ADT with
an increased risk of diabetes, stroke, fatal and non-fatal myocardial
infarction in men with prostate cancer. In an observational study of
14,597 men with local or regional prostate cancer (Keating et al,
2010) reported a significantly higher risk of diabetes (HR¼ 1.28),
coronary heart disease (HR¼ 1.19), myocardial infarction
(HR¼ 1.28), sudden cardiac death (HR¼ 1.35) and stroke
(HR¼ 1.22) on LHrH analogues when compared to men not
taking these agents. Data from the Swedish cancer registry
including 30,642 men with prostate cancer show a 40% higher
rate of myocardial infarction in men undergoing primary ADT
(Van Hemelrijck et al, 2010). A cohort study with nested case–
control analysis from the UK General Practice Research Database
(n¼ 5103) also reported significantly elevated risks of coronary
heart disease (OR¼ 4.35), acute myocardial infarction (OR¼ 3.57),
heart failure (OR¼ 3.19) and hospitalisation for heart failure
(OR¼ 3.39) in men undergoing combination therapy (LHrH
agonists and anti-androgens) compared with men not on this
treatment (Martin-Merino et al, 2011). This emerging evidence has
led to a recent joint science advisory statement by the American
Heart Association, The American Cancer Society and the
American Urological Association asserting that it is possible that
ADT could increase cardiovascular risk on the basis of its adverse
impact on risk factors (Levine et al, 2010). The over-riding message
is that a cause and effect relationship between ADT and increased
risk of CVD remains a plausible hypothesis that is yet to be
falsified.
Such evidence remains circumstantial and there are limitations
to drawing conclusions from cancer registries as analysis of non-
cancer outcomes can be problematic due to missing data and
unmeasured confounders, for example the resolution of data on
cardiovascular disease severity is often not recorded as assiduously
as cancer-specific data. Given that prostate cancer is a disease of
elderly men, with a protracted natural history and that CVD may
take decades to manifest from a constellation of risk factors, these
caveats are worth careful consideration when evaluating the
observational data. Hence, it is still unclear whether this reflects
a causal relationship.
Is there direct evidence of a link between LHrH analogues and
CVD morbidity/mortality?. Whereas convincing observational
data and plausible mechanisms have been reported, there is no
level 1 evidence linking LHrH analogues with an increase in CVD
mortality/morbidity. However, cardiovascular safety was initially
declared on the basis of use in 12 patients (Waxman et al, 1983)
and no randomised controlled trial has ever assessed cardiovas-
cular morbidity and/or mortality as a primary outcome in men
undergoing ADT by LHrH analogues. A recent meta-analysis
(Nguyen et al, 2011) sought to synthesise such evidence. The
article, reported as a comparison of exposure to ADT with non-
exposure in matched subjects, synthesised data from studies
reporting CVD mortality as an adverse event rather than a primary
outcome. The meta-analysis concluded that treatment with ADT is
not associated with any increased risk of CVD mortality
(HR¼ 0.93, 95% CI¼ 0.79, 1.10), with the results being described
as ‘reassuring’. However, as has been pointed out elsewhere
(Blankfield, 2012) methodological flaws cast doubt over this
conclusion. Almost half the men (1930/4141) came from RTOG
85-31, as reported by Efstathiou (Efstathiou et al, 2009) to
investigate ‘lifelong’ exposure to ADT and from a multicentre
European study (Studer et al, 2006) examining immediate versus
deferred ADT. Previous publications from RTOG 85-31 have
reported 72% (n¼ 322) of men in the intervention arm as having
discontinued ADT early (Souhami et al, 2009), thus leading to
uncertainty as to duration of exposure. The comparator ‘control’
arm in the European study included men with substantial
exposures to ADT, with around 25% of men in the deferred group
being commenced on ADT within 3 years of randomisation.
We recalculated the meta-analysis summary statistic (D’Amico
et al, 2008; Roach et al, 2008; Bolla et al, 2010; Denham et al, 2011)
removing data from RTOG 85-31 (Efstathiou et al, 2009) and trials
that compared immediate with deferred ADT (Messing et al, 2006;
Studer et al, 2006; Schroder et al, 2009) (see Table 1), where there
had been contamination of the control group. Importantly the
Table 1. Recalculation of a meta-analysis of CVD mortality due to use of AST first presented by Nguyen et al
AST Control Risk ratio
Study
Median AST duration
(months) Events Total Events Total Weight (%)
M-H, Random,
95% CI
D’Amico et al (2008) 6 13 102 13 104 15.1 1.02 (0.50, 2.09)
Bolla et al (2010) 36 22 207 17 208 21.4 1.30 (0.71, 2.38)
Roach et al (2008) 4 31 224 26 232 32.7 1.23 (0.76, 2.01)
Denham et al (2011) 3–6 36 532 23 270 30.8 0.79 (0.48, 1.31)
Total (95% CI) 1065 814 1.06 (0.80, 1.40)
Total events 102 79
Abbreviations: CI, confidence interval; CVD, cardiovascular disease.
Heterogeneity: I2¼ 0% (P¼ 0.55). Test for overall effect: Z¼ 0.40 (P¼ 0.69).
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median duration of ADT is only 6 months, which is considerably
shorter exposure than is used in clinical practice for the majority of
men on ADT. The result still indicates that for these combined
radiotherapy trials, there is no significant increase in the risk of
CVD mortality seen through the use of ADT (RR¼ 1.06; 95%
CI¼ 0.80,1.40). The confidence interval is however wider than in
the previous meta-analysis, as a result of having excluded the two
largest trials and the conclusion is therefore open to question. The
confidence interval of this, arguably more appropriate, pooled
estimate is consistent with CVD risk being as much as 40% greater
with ADT in some men. Given the observations above, can the
scientific and clinical community and, above all, men with prostate
cancer truly be reassured that CVD mortality is not a legitimate
concern? And how should the risk of potential CVD morbidity be
considered?
Based on the available data, it remains plausible that men on
long-term ADT are at increased risk, but we do not reliably know
the degree of risk, who is at risk nor how best to minimise this risk.
The only research design that will give us definitive cause and effect
evidence is a multicentre randomised controlled trial with primary
cardiovascular morbidity/mortality endpoints, however, given the
circumstances, such a study is unlikely. In its absence, a bespoke
synthesis of data from studies comparing men on long-term ADT
to matched controls with high detail resolution on CVD outcomes
to construct an individual patient data meta-analysis with
integrated meta-regression to elucidate dose responses, could be
highly informative. Without such studies, we are likely to be
presented year after year with more observational data: all with the
same inherent problems of bias due to, inter alia, non-randomisa-
tion, non-validation of CVD mortality, and incomplete assessment
of pertinent co-morbidity.
IS THE TREATMENT COST-EFFECTIVE?
Decisions made by NICE about whether cost effective treatments
are approved for use in the NHS usually apply a threshold of
around d20 000–d30 000 per QALY. Neither the Department of
Health nor NICE hold any data on the cost-effectiveness or QALYs
for conventional ADT drugs such as GNrH/LHrH analogues.
Given the relative lack of evidence of benefit of long-term ADT,
can we really justify spending nearly d100m on a class of drugs,
with an uncertain long-term safety profile?
It is inevitable, that should a man survive long enough on ADT,
castrate-resistant prostate cancer will develop and until recently,
few treatment options had been shown to be effective in improving
overall survival in men with such disease. Taxane-based
chemotherapy has been shown to be effective in this group of
men, but is associated with significant toxicity. Several agents are
currently showing promise in this group of men, with NICE having
initially evaluated Abiraterone, an inhibitor of androgen synthesis
at d63 200 per QALY and deeming it not to be cost-effective,
further stating that the criteria for an end-of-life treatment were
not met (for which the thresholds could be increased). This
decision was reversed in June 2012 after the manufacturer
(Janssen) has lowered the cost to an ‘‘undisclosed lower price’’.
Enzalutamide, a novel androgen receptor antagonist has recently
been shown to be effective in prolonging survival in men with
castrate-resistant prostate cancer following failure of taxane
chemotherapy (Scher et al, 2012) Whereas such advances
potentially represent good news for men with prostate cancer, it
must be recognised, that the inclusion criteria into the studies has
been on the basis of failure of docetaxel. Studies are now underway
evaluating the role of Abiraterone in localised/ high risk disease
(i.e. the addition of Abiraterone to the STAMPEDE trial). Prostate
cancer, including castrate-resistant prostate cancer, represents a
spectrum of disease from a rising PSA level through to rapidly
progressive clinically-evident disease. Unless the indications
(including precise stage of disease) for using these drugs are
clearly defined in advance, as well as the potential toxicities
associated with long-term use, significant migration in costs and
possible adverse events, as has occurred with existing conventional
ADT, may ensue. Therefore, a better understanding of the
potential risks and any excess treatment cost associated with
ADT is imperative to inform how cost effective these drugs
truly are.
CONCLUSIONS
There is good evidence that treatment of advanced prostate cancer
by ADT results in improvements in symptoms in men with end-
stage disease but, at best, weak evidence for improvement in
survival, except when combined with radical local treatment,
particularly radiotherapy. With the advent of PSA testing and more
aggressive treatment, men are remaining on ADT for much longer
than might have been originally anticipated. Newer, more potent
agents have now become available, and although survival benefit
for these has been shown in end-stage castrate-resistant disease, it
is only a matter of time before they will be considered in earlier
disease, possibly as a new form of maximal androgen blockade.
Within this context, it seems reasonable to re-evaluate the evidence
and consider questions for further studies to address. These include
(i) Which stages of prostate cancer warrant treatment and with
which agent? (ii) In which men with prostate cancer can any form
of ADT be safely deferred? (iii) Do existing co-morbidities put men
at increased CVD risk with ADT? (iv) Will more effective
androgen deprivation, as possible with newer agents, result in
higher risks when used for longer than has currently been
investigated and how should these be measured? (v) What
interventions mitigate any increased risk of CVD? (vi) What are
the true benefits of treatment when the patient is viewed
holistically and what are the full costs to the NHS, including
treatment of adverse events associated with these drugs. The
expansion of indications in the pursuit of cancer-specific benefit
may result in men being on combined, highly potent, expensive
androgen deprivation for many years, at great cost and with
possible attendant risks. Therefore a better understanding of these
risks and any excess treatment cost associated with ADT is
imperative to inform how cost effective these drugs truly are and
whether interventions are available to reduce their risks.
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